DEA inspections, investigations, registration defense, administrative subpoenas, and controlled-substance compliance for ketamine clinics and providers
A DEA matter involving a ketamine clinic rarely stays confined to one question or one person. A single practice may involve an owner, medical director, employed clinicians, independent contractors, multiple treatment locations, and several DEA registrations. When DEA begins reviewing the clinic, the same records can create different issues for different registrants.
Ketamine clinics also sit at the intersection of several regulatory issues at once. DEA may be examining where ketamine was ordered and stored, which registrations cover which locations, how administrations and prescriptions were documented, whether telemedicine or at-home prescribing complied with the rules in effect, and what the clinical record shows about the treatment itself.
Those questions overlap with the broader federal standards governing DEA-registered healthcare prescribers and with the registration, recordkeeping, inspection, and enforcement framework discussed on Jani Law’s DEA Regulatory Defense and Investigations page.
Dhairya Jani served as DEA Diversion Enforcement Counsel in the DEA Office of Chief Counsel, where he administratively prosecuted registration matters under the Controlled Substances Act. Jani Law PLLC now represents DEA registrants in inspections, investigations, administrative subpoenas, civil penalty matters, Orders to Show Cause, Immediate Suspension Orders, negotiated resolutions, and hearings before DEA Administrative Law Judges.
If DEA has contacted your ketamine clinic, medical director, or one of your providers, Jani Law PLLC offers a free, confidential consultation. Call 202-899-2711 or contact Jani Law PLLC to discuss the matter directly with Dhairya Jani.
Common Reasons Ketamine Clinics Contact Jani Law
Ketamine clinics and individual providers often reach out when one of these issues has already surfaced:
- DEA Diversion Investigators arrive for an inspection or request controlled-substance records.
- The clinic is unsure whether the DEA registrations on file match the locations where ketamine is stored or administered.
- Investigators identify an inventory, receiving, administration, wastage, transfer, or recordkeeping issue.
- The clinic receives a DEA administrative subpoena involving its own records, particular providers, patients, or a telemedicine relationship.
- DEA begins asking about treatment documentation, prescribing patterns, at-home ketamine, or the relationship between a provider and patient.
- The clinic offers both racemic ketamine and Spravato and questions arise about how the two programs are documented or operated.
- Different providers within the same clinic may have different facts, responsibilities, or exposure.
- DEA raises potential Controlled Substances Act violations, civil penalties, a Memorandum of Agreement, an Order to Show Cause, or an Immediate Suspension Order.
DEA Is Inspecting Your Ketamine Clinic: What Does That Mean?
A regulatory inspection and the first visible step of a larger investigation can look similar at the beginning. DEA personnel may ask to inspect controlled-substance records, review storage and security, compare inventory with administration records, or ask questions about particular providers or locations. The scope often becomes clearer only after investigators review the records and begin asking more focused questions.
For a clinic owner, medical director, or individual registrant, the important point is that the inspection may be evaluating more than one layer of the practice at the same time. A location issue can lead to recordkeeping questions. A recordkeeping issue can lead to scrutiny of who ordered or administered the drug. A prescription or clinical-record review can become an individualized inquiry into a particular provider.
DEA contact does not by itself establish a violation. But once investigators are reviewing the clinic, it is useful to understand which registration, location, provider, and set of records are actually within the inquiry.
Why Ketamine Clinics Present Different DEA Risks
There is no separate DEA registration category called a ketamine clinic. Ketamine is a Schedule III controlled substance, and the ordinary Controlled Substances Act framework applies. What makes the clinic model different is how many regulatory questions can converge in one operation.
One business may involve several DEA registrants
A clinic may operate under one business name while the controlled-substance authority belongs to individual practitioners or other registered entities. DEA can evaluate those registrants separately even when they work from the same policies, staff, and physical space.
Ketamine may be stored, administered, prescribed, or dispensed
Those activities are related, but they are not interchangeable. The registration and recordkeeping analysis can change depending on what the clinic is actually doing with the controlled substance, who is doing it, and where the activity occurs.
The clinical record can become part of the DEA record
When DEA questions the legitimacy of prescribing or administration, the inquiry can move beyond inventory and into the documented evaluation, treatment rationale, contraindications, dose selection, monitoring, response, and follow-up.
Telemedicine and at-home treatment add another layer
Remote prescribing can raise questions about the federal telemedicine framework, the practitioner-patient relationship, state authority, and what the clinic documented before issuing a controlled-substance prescription.
Does Every Ketamine Clinic Location Need Its Own DEA Registration?
The answer depends on the controlled-substance activity occurring at the location, the registrant involved, and whether an applicable exception applies. The more useful question is not simply whether the clinic has a DEA number. It is whether the registrations on file match how ketamine is actually ordered, received, stored, administered, prescribed, or otherwise handled at each location.
As a general rule, 21 C.F.R. § 1301.12 requires a separate registration for each principal place of business or professional practice where controlled substances are manufactured, distributed, or dispensed, subject to the regulation’s exceptions. For DEA purposes, dispensing includes administering a controlled substance.
Registration questions commonly arise when:
- ketamine is stored or administered at a location not reflected in the relevant registration structure;
- a second clinic location opens before the controlled-substance registrations are fully aligned with the new operation;
- one provider orders stock that is then used across a multi-provider practice;
- controlled substances move between clinic locations without records that match the actual transfer; or
- the clinic assumes that the business entity, medical director, or another provider’s registration necessarily covers everyone handling ketamine at the location.
Public enforcement matters involving ketamine clinics show why location and recordkeeping issues deserve attention. In one ketamine-specific civil settlement, the government alleged that ketamine was distributed from an unregistered location and that required controlled-substance records were not maintained. The matter resolved without an admission of liability.
What DEA May Examine at a Ketamine Clinic
The scope depends on the reason for the visit and what investigators encounter. Common areas can include:
Registration by provider and location
Investigators may compare the registrations on file with the locations where ketamine is ordered, received, stored, administered, or prescribed and with the people actually handling the drug.
Ordering, receiving, inventory, and controlled-substance flow
DEA may examine who ordered the ketamine, where it was delivered, how much was received, what remains in stock, what was administered or otherwise dispensed, and how wastage, transfers, returns, or destruction were documented.
Security and storage
Ketamine is a Schedule III controlled substance. 21 C.F.R. § 1301.75 generally requires practitioners to store Schedule II through V controlled substances in a securely locked, substantially constructed cabinet and to maintain effective controls against theft and diversion.
Inventories and records
DEA may review the initial and biennial inventory requirements in 21 C.F.R. § 1304.11, along with the records needed to account for controlled substances received and handled at the clinic.
Theft or significant loss
If controlled substances are missing, 21 C.F.R. § 1301.76(b) contains time-sensitive reporting requirements for theft or significant loss. Whether a particular variance meets that standard is fact-specific.
Clinical documentation and treatment rationale
When the government questions prescribing or administration, investigators may review the clinical record for the evaluation, diagnosis, treatment rationale, contraindications, dosing, monitoring, response, and follow-up that supported the treatment decision.
Does Off-Label Ketamine Create DEA Exposure?
Off-label treatment, by itself, does not make ketamine prescribing or administration unlawful. Ketamine is FDA-approved as an anesthetic, and its use for depression, PTSD, anxiety, and many chronic-pain protocols is generally off-label. The DEA question is different: whether the controlled substance was prescribed, administered, stored, and documented consistently with the law that applies to the registrant and the treatment model.
For a controlled-substance prescription, 21 C.F.R. § 1306.04(a) requires a legitimate medical purpose and issuance by a practitioner acting in the usual course of professional practice. When ketamine is administered directly in the clinic rather than prescribed to the patient, the legal analysis is not simply a copy of the prescription rule.
For a clinic under review, the practical question is often what the existing clinical record shows. A note that ketamine was given tells a different story from a record that documents why it was chosen, what risks were considered, how the dose was selected, how the patient was monitored, and what happened afterward.
Ketamine and Spravato Are Different Compliance Programs
Some clinics offer both racemic ketamine and esketamine marketed as Spravato. They should not be treated as interchangeable from a compliance standpoint.
Spravato is subject to an FDA Risk Evaluation and Mitigation Strategy. The Spravato REMS requirements impose a separate framework for certified healthcare settings, supervised self-administration, and post-dose monitoring. Racemic ketamine used off-label does not operate under that REMS.
For a clinic offering both treatments, separate workflows, inventory controls, policies, and documentation can help make clear which framework applies to which patient and product.
Ketamine Prescribing Through Telemedicine
Telemedicine remains a time-sensitive area of federal controlled-substance law. As of September 2026, DEA and HHS have extended the temporary federal telemedicine flexibilities for controlled-substance prescribing through December 31, 2026.
Under the current temporary federal framework, a DEA-registered practitioner may, when all applicable requirements are satisfied, prescribe controlled substances through qualifying telemedicine encounters without first conducting an in-person medical evaluation. The temporary rule does not eliminate the underlying requirements governing the prescription or the practitioner’s state authority.
For a ketamine clinic built partly or primarily around remote prescribing, the facts that matter can include where the practitioner and patient are located, what evaluation occurred, what was documented, whether the prescription was for home use, and which federal and state rules applied at the time.
One Clinic, Multiple DEA Registrants
A ketamine clinic may function as one business, but the DEA exposure often does not. The registration belongs to the registrant, and DEA can evaluate the conduct of individual providers separately.
Separate providers can face separate questions
An owner, medical director, physician, nurse practitioner, physician assistant, or independent contractor may have different prescribing, administration, documentation, and registration facts. The fact that everyone followed the same clinic policy does not necessarily produce the same analysis for each provider.
The clinic and individual providers may not have identical interests
A clinic-level explanation may not fit every registrant. One provider may have handled a particular location, patient group, or set of records differently from another. As the inquiry develops, representation may need to be evaluated by registrant and by issue.
Records can move the inquiry from one provider to another
DEA may begin by reviewing the clinic and then focus on particular prescribers or administrators based on what the records show. A provider may also become a source of information relevant to another registrant’s matter.
If DEA Identifies a Problem, What Could Happen Next?
Not every inspection or records review leads to enforcement. When DEA identifies issues it wants to pursue, however, the matter can move in several directions.
Additional records requests or interviews
Investigators may request additional records, expand the time period under review, ask about specific patients or providers, or seek interviews with clinic personnel.
DEA administrative subpoena
A subpoena may seek clinical records, controlled-substance records, communications, or information concerning particular providers or patients. Scope, preservation, privilege, certification, and production strategy can matter before records are produced. Jani Law’s guide to DEA administrative subpoenas discusses that process in more detail.
Civil penalties or negotiated resolution
Controlled Substances Act civil penalties can be assessed on a per-violation basis. Depending on the matter, DEA may also pursue a negotiated resolution with reporting, training, audit, prescribing, recordkeeping, or operational requirements that can affect the clinic for years.
Order to Show Cause or Immediate Suspension Order
An Order to Show Cause begins formal DEA administrative proceedings involving the registration. An Immediate Suspension Order can suspend controlled-substance authority immediately when DEA invokes the statutory imminent-danger standard. If an Order to Show Cause has already been served, Jani Law’s guide to the first thirty days after a DEA Order to Show Cause explains the transition from investigation to formal proceedings.
DEA Just Arrived at the Clinic: Questions Worth Clarifying Early
Every inspection is different, and a general webpage cannot tell a clinic how to respond to a particular visit. Several threshold questions can help frame what is happening and what may need closer review.
What authority is DEA using?
A consent-based administrative inspection, an administrative inspection warrant, an administrative subpoena, and an interview request involve different authorities and different issues. The documents presented at the outset can help identify which process is underway.
Which registration and location are within the inquiry?
For a multi-provider or multi-location practice, it can be important to identify which DEA registrant, clinic address, and controlled-substance activity investigators are actually reviewing.
What records are being requested or reviewed?
Ketamine records may sit across ordering, receiving, inventory, administration, clinical, billing, telemedicine, and other systems. Understanding the existing record and how those systems connect can become important when DEA is trying to reconstruct what occurred.
Are there questions the clinic cannot answer accurately yet?
An apparent inventory discrepancy, registration issue, or documentation question may require reconstruction before its significance is understood. In an active matter, the distinction between what the clinic knows, what it is still evaluating, and what the records ultimately establish can be important.
Could different registrants have different interests?
The clinic, medical director, owner, employed providers, and independent contractors may not have identical facts or exposure. A matter that begins as a clinic-level review can later become individualized.
When Should a Ketamine Clinic Call DEA Regulatory Counsel?
A ketamine clinic does not need to wait for an Order to Show Cause or a formal allegation before speaking with DEA regulatory counsel. In many matters, the useful time to understand the clinic’s exposure is while DEA is still gathering records, reviewing registrations, or deciding what the facts mean.
A consultation may be particularly useful when:
- DEA arrives for an inspection and the clinic is uncertain about the authority, scope, or records being requested;
- the clinic is trying to determine whether its providers and locations are properly registered for the controlled-substance activity actually occurring;
- investigators identify an apparent inventory, receiving, administration, wastage, transfer, security, or recordkeeping issue;
- DEA begins asking questions about a particular provider, treatment protocol, prescribing pattern, or clinical record;
- the clinic receives an administrative subpoena involving its own operations, a provider, patient group, or telemedicine relationship;
- questions arise about at-home ketamine, remote prescribing, or the federal telemedicine framework;
- different providers within the same clinic may have different responsibilities or interests;
- the clinic is considering corrective action and wants to understand how the response may be evaluated by DEA; or
- DEA raises a potential civil penalty, Memorandum of Agreement, Order to Show Cause, or Immediate Suspension Order.
The value of early counsel is not to change the underlying facts. It is to understand what DEA is examining, identify what the existing record actually shows, separate preliminary assumptions from supported findings, and evaluate the registration, recordkeeping, prescribing, and provider-specific issues together rather than one request at a time.
If DEA has contacted your ketamine clinic and you are trying to understand what the contact means or what may come next, call 202-899-2711 or contact Jani Law PLLC for a free, confidential consultation.
How Jani Law PLLC Helps in a Ketamine Clinic DEA Matter
Some clinics call while investigators are still on site. Others call after a records request, subpoena, registration issue, or formal charging document has arrived. Jani Law PLLC represents DEA registrants at each of those stages.
Inspection and investigation response
Evaluating the authority and scope of DEA contact, organizing the existing record, identifying which registrants and locations are implicated, and assessing the issues investigators appear to be developing.
Registration and controlled-substance flow analysis
Mapping the clinic as it actually operates: who orders ketamine, where it is delivered, where it is stored, who has access, who administers or prescribes it, and how the drug is documented through final disposition.
Clinical-record and expert review
When DEA challenges the medical basis for treatment or the usual course of professional practice, Jani Law PLLC separates the legal issues from medical judgment and works with qualified independent experts where appropriate.
Administrative subpoena response
Reviewing scope, legal authority, preservation, privilege, certification, production format, and whether explanatory context is appropriate before records are produced.
Corrective action and negotiated resolution
Developing remediation that can be documented and tested, and evaluating or negotiating Memorandum of Agreement terms that may affect registration, prescribing, reporting, audit, training, or operations for years.
Order to Show Cause, Immediate Suspension Order, and civil penalty defense
Representing registrants in formal DEA administrative proceedings and addressing civil penalty exposure in parallel. Where criminal exposure exists, Jani Law PLLC can coordinate the federal regulatory defense with separately retained criminal counsel.
Ketamine Clinic DEA Defense FAQs
These answers provide general orientation only. The significance of a DEA inspection, subpoena, registration issue, prescribing concern, or enforcement action depends on the facts, the authority DEA is using, the clinic’s records, and the law that applies to the particular matter. For broader DEA questions, see Jani Law’s DEA Defense FAQs.
Potentially. Lawful medical use does not remove ketamine from the Controlled Substances Act. DEA may examine registration, prescribing, administration, storage, inventory, recordkeeping, diversion, and other controlled-substance issues. The fact that a treatment is off-label does not, by itself, establish a violation.
The answer depends on the controlled-substance activity at the location, the registrant involved, and any applicable exception. A clinic that stores or administers ketamine at multiple locations may want to examine whether its registration structure matches how the practice actually operates rather than assuming one address or one provider’s registration covers the entire business.
It depends on the authority being used. DEA regulations contemplate administrative inspections conducted with informed consent, with an administrative inspection warrant, and in certain circumstances where a warrant is not required. If investigators are requesting consent, the legal and practical considerations can be fact-specific.
Under the temporary federal flexibilities currently in effect, qualifying controlled-substance prescriptions may be issued through telemedicine without a prior in-person medical evaluation when the federal and state requirements are satisfied. Those temporary flexibilities currently run through December 31, 2026. Because the framework is time-sensitive, the rule in effect on the date of prescribing should be confirmed.
No single answer about DEA exposure turns on the off-label label alone. Off-label use is common in medicine and is not, by itself, unlawful. DEA issues can arise from the controlled-substance activity surrounding the treatment, including registration, prescribing, administration, documentation, storage, and recordkeeping.
Potentially. DEA registrations and provider conduct can be evaluated separately. A multi-provider clinic may therefore produce different questions, allegations, defenses, or resolutions for different registrants even when they practice under the same business name.
A DEA administrative subpoena is a formal investigative demand, not an ordinary records request. Its significance depends on what is requested and why. Scope, preservation, privilege, certification, and production strategy may all matter before records are produced. Jani Law’s administrative subpoena guide explains the process in more detail.
They can. Recordkeeping allegations may support civil penalties and can become part of DEA’s broader public-interest analysis. The significance of a particular problem depends on the nature of the records, the duration and scope of the issue, the surrounding facts, the registrant’s history, and what the evidence actually establishes.
At that point the matter has moved into formal administrative proceedings involving the DEA registration. The controlling deadlines are the ones stated in the documents actually served. Jani Law’s Order to Show Cause guide explains the transition from investigation to formal DEA litigation and the early decisions that may need attention.
DEA Contacted Your Ketamine Clinic? Talk With Jani Law PLLC.
A clinic owner, medical director, or provider often calls before anyone knows exactly where the matter is going. DEA may be reviewing a location, reconciling controlled-substance records, asking about a particular provider, examining telemedicine prescribing, or seeking clinical records. The immediate task is to understand what the agency is actually examining and what the existing record shows.
Early counsel cannot change the facts. It can help identify which facts matter, evaluate the clinic and individual registrants together, and respond to an evolving DEA matter with the registration, recordkeeping, prescribing, and enforcement issues all in view.
Dhairya Jani served as DEA Diversion Enforcement Counsel before founding Jani Law PLLC. The firm provides DEA regulatory defense and investigation representation to healthcare prescribers, clinics, pharmacies, distributors, manufacturers, and other DEA registrants nationwide.
The initial consultation is free and confidential. Call 202-899-2711 or contact Jani Law PLLC online to discuss the DEA matter directly with Dhairya Jani.